Facial Skin Aging and DullnessNCT07156071
12-Week Study on the Efficacy of Two Serums in Improving Skin Aging and Tone
A study testing Serum 1 and Serum 2 in people with Facial Skin Aging and Dullness, run by ChinaNorm at 1 site in China.
Trial summary
This study aims to evaluate the anti-aging and skin tone improvement effects of two facial serums over a 12-week period. It was conducted at a single research center with a 2-week washout period followed by full-face application of the test products for 12 weeks. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Facial Skin Aging and Dullness
- What is being tested?
- Serum 1 and Serum 2
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 18 Nov 2023to 22 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Chinese female aged 18-45 years (evenly split among Early aging [18-29 years] and Mature aging [30-45 years]).
- All skin types (dry, normal, oily, or mixed).
- Currently experiencing lack of radiance, roughness, dullness, and fine lines or wrinkles on facial skin as self-claimed.
- Early aging group (18-29 years): Must present with corresponding severity for the attributes evaluated by Dermatologist, including:
- Skin smoothness, radiance, dullness: grade between 2 and 6 (scale 0-9);
- Size of acne marks (PIH): size ≥ 2;
Show all 18Show fewer
- Small folds on nasolabial zone: grade between 1 and 3 (Skin Aging Atlas, 0-6 scale, Page 56-57).
- Mature aging group (30-45 years): Must present with corresponding severity for the attributes evaluated by Dermatologist, including:
- Skin smoothness, radiance, dullness: grade between 4 and 6 (scale 0-9);
- Small folds on nasolabial zone: grade between 1 and 4 (Skin Aging Atlas, 0-6 scale, Page 56-57);
- Forehead wrinkles: grade ≥ 2 (Skin Aging Atlas, 0-8 scale, Page 32-33);
- Crow's feet wrinkles: grade ≥ 2 (Skin Aging Atlas, 0-6 scale, Page 40-41).
- Regular user of serum and sunscreen products.
- Did not participate in any clinical test or cosmetic product test on skin within the last 3 months.
- No exclusion by dermatologist due to other medical or dermatological reasons.
- In general good health at the time of the study.
- Willing and able to participate as evidenced by signing of informed consent and photo release form.
- Must be willing to comply with all study protocol requirements (including using only the skincare products provided during the study and not taking topical or oral treatments such as retinol, hormones, or antioxidant health supplements).
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072
Shanghai
About this study
Official title: 12-Week Serum Efficacy Study
This study aims to evaluate the anti-aging and skin tone improvement effects of two facial serums over a 12-week period. It was conducted at a single research center with a 2-week washout period followed by full-face application of the test products for 12 weeks.
A total of at least 120 healthy Chinese female participants aged 18 to 45 were enrolled and divided into two treatment groups:Each group included both early aging (18-29 years) and mature aging (30-45 years) subgroups, with at least 30 participants in each subgroup.
- Conditions
- Facial Skin Aging and Dullness
- Being tested
- Serum 1, Serum 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum 1Other
Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 1 group.
Serum 2Other
Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 2 group.
| Study group | Role | What they receive |
|---|---|---|
| Serum 1 Group | Experimental | Participants in this arm applied Serum 1 (Fla#897183 329) to the full face twice daily for 12 weeks. The group included both early aging (18-29 years) and mature aging (30-45 years) subgroups. Receives: Other: Serum 1 |
| Serum 2 Group | Experimental | Participants in this arm applied Serum 2 (Fla#b50198) to the full face twice daily for 12 weeks. The group included both early aging (18-29 years) and mature aging (30-45 years) subgroups. Receives: Other: Serum 2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Dermatologist-Assessed Wrinkle Attributes
Crow's feet wrinkles, forehead wrinkles, global wrinkles, small folds on nasolabial zone and global fine lines will be evaluated by dermatologist.
Measured: from Baseline to Week 12
Self-assessment Questionnaire
Participants will complete a 5-point self-assessment questionnaire at Timm, T4w, T8w, and T12w, evaluating their perception of skin softness, smoothness, plumpness, elasticity, hydration, oil control, and visible aging signs. Ratings from 4 to 5 will be used to calculate "Top 2 box" percentage.
Measured: 12 weeks
Change in Dermatologist-Assessed Skin Texture and Quality Attributes
Skin smoothness (visual), skin elasticity, skin softness, skin firmness, skin plumpness, cheek pores will be evaluated by dermatologist.
Measured: from Baseline to Week 12
Change in Dermatologist-Assessed Skin Tone Attributes
Skin radiance, skin translucency, skin pigmentation, skin fairness, skin tone evenness and skin dullness will be evaluated by dermatologist.
Measured: from Baseline to Week 12
Secondary outcomes (5)
Change in Skin Hydration Measured by Corneometer
Measured: 12 weeks
Change in Skin Elasticity Measured by Cutometer
Measured: 12 weeks
Change in Transepidermal Water Loss (TEWL) Measured by Vapometer
Measured: 12 weeks
Change in Facial Image-Based Skin Parameters Using VISIA-CR
Measured: 12 weeks
Change in Cheek Skin Surface Condition Using VisioScan VC20
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2025
- Study start18 Nov 2023
- Primary completion1 Mar 2024
- Study completion22 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facial Skin Aging and DullnessStudies of the same condition, open and under way.
- More trials run by ChinaNormThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Parallel groups
- Model description
- Participants were assigned in parallel to one of two serum groups (Serum 1 or Serum 2), based on stratification by aging type (early aging or mature aging). The products were applied twice daily over 12 weeks.
- Masking
- None (open label)
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- ChinaNorm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07156071
- Sponsor's protocol ID
- C23005059
- Status last verified
- Sep 2025
- First submitted
- 20 Aug 2025
- Last updated
- 8 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 12-Week Serum Efficacy Study
- ClinicalTrials.gov ID
- NCT07156071
- Acronym / sponsor ID
- C23005059
- Conditions
- Facial Skin Aging and Dullness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- ChinaNormIndustry (pharma, biotech, devices)
- Study start
- 18 Nov 2023 (actual)
- Primary completion
- 1 Mar 2024 (actual)
- Study completion
- 22 Mar 2024 (actual)
- First posted
- 4 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the anti-aging and skin tone improvement effects of two facial serums over a 12-week period. It was conducted at a single research center with a 2-week washout period followed by full-face application of the test products for 12 weeks.
A total of at least 120 healthy Chinese female participants aged 18 to 45 were enrolled and divided into two treatment groups:Each group included both early aging (18-29 years) and mature aging (30-45 years) subgroups, with at least 30 participants in each subgroup.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants were assigned in parallel to one of two serum groups (Serum 1 or Serum 2), based on stratification by aging type (early aging or mature aging). The products were applied twice daily over 12 weeks.
| Arm | Type | Receives |
|---|---|---|
| Serum 1 Group | Experimental | Other: Serum 1Participants in this arm applied Serum 1 (Fla#897183 329) to the full face twice daily for 12 weeks. The group included both early aging (18-29 years) and mature aging (30-45 years) subgroups. |
| Serum 2 Group | Experimental | Other: Serum 2Participants in this arm applied Serum 2 (Fla#b50198) to the full face twice daily for 12 weeks. The group included both early aging (18-29 years) and mature aging (30-45 years) subgroups. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (18 listed)
- Chinese female aged 18-45 years (evenly split among Early aging [18-29 years] and Mature aging [30-45 years]).
- All skin types (dry, normal, oily, or mixed).
- Currently experiencing lack of radiance, roughness, dullness, and fine lines or wrinkles on facial skin as self-claimed.
- Early aging group (18-29 years): Must present with corresponding severity for the attributes evaluated by Dermatologist, including:
- Mature aging group (30-45 years): Must present with corresponding severity for the attributes evaluated by Dermatologist, including:
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serum 1Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 1 group. | Other | Serum 1 Group |
| Serum 2Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 2 group. | Other | Serum 2 Group |
Primary outcome
Change in Dermatologist-Assessed Wrinkle Attributes
Time frame: from Baseline to Week 12
Crow's feet wrinkles, forehead wrinkles, global wrinkles, small folds on nasolabial zone and global fine lines will be evaluated by dermatologist.
Self-assessment Questionnaire
Time frame: 12 weeks
Participants will complete a 5-point self-assessment questionnaire at Timm, T4w, T8w, and T12w, evaluating their perception of skin softness, smoothness, plumpness, elasticity, hydration, oil control, and visible aging signs. Ratings from 4 to 5 will be used to calculate "Top 2 box" percentage.
Change in Dermatologist-Assessed Skin Texture and Quality Attributes
Time frame: from Baseline to Week 12
Skin smoothness (visual), skin elasticity, skin softness, skin firmness, skin plumpness, cheek pores will be evaluated by dermatologist.
Change in Dermatologist-Assessed Skin Tone Attributes
Time frame: from Baseline to Week 12
Skin radiance, skin translucency, skin pigmentation, skin fairness, skin tone evenness and skin dullness will be evaluated by dermatologist.
5 secondary outcomes
Change in Skin Hydration Measured by Corneometer
Time frame: 12 weeks
Change in Skin Elasticity Measured by Cutometer
Time frame: 12 weeks
Change in Transepidermal Water Loss (TEWL) Measured by Vapometer
Time frame: 12 weeks
Change in Facial Image-Based Skin Parameters Using VISIA-CR
Time frame: 12 weeks
Change in Cheek Skin Surface Condition Using VisioScan VC20
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2025.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Serum 1 and Serum 2 in people with Facial Skin Aging and Dullness, run by ChinaNorm at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Dermatologist-Assessed Wrinkle Attributes (time frame: from Baseline to Week 12). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2025.